首页> 外文OA文献 >CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress

【2h】

CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress

机译：Canstem303C试验：在成年患者（PTS）中与先前治疗的转移性结肠直肠癌（MCRC）的成人患者（PTS）组合的纳帕布桑（NAPA）与5-氟尿嘧啶（5-FU），Leucovorin和Irinotecan（Folfiri）的相结合研究 - 试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
M. Shah; A. Grothey; N. Tebbutt; R. Xu; T. Yoshino; A. Cervantes; J. Tabernero; J. Taieb; A. Falcone; B. Xu; M. Fontaine; L. Borodyansky; E. Van Cutsem;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 6012 The FIRIS study; A Phase III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 2nd-line chemotherapy for metastatic colorectal cancer (mCRC) [FIRIS study group] [J] . K.Kato, K.Muro, H.Yasui, European Journal of Cancer Supplements . 2009,第2期

机译：6012 FIRIS研究; 5-FU / 1-亚叶酸钙蛋白/伊立替康（FOLFIRI）与伊立替康/ S-1（IRIS）作为转移性结直肠癌（mCRC）二线化疗的III期临床试验[FIRIS研究组]
2. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. [J] . Souglakos J, Pallis A, Kakolyris S, Oncology: International Journal of Cancer Research and Treatment . 2005,第5期

机译：伊立替康（CPT-11）加5-氟尿嘧啶和亚叶酸（FOLFIRI方案）的组合作为老年转移性结直肠癌患者的一线治疗：II期试验。
3. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable|[sol]|metastatic colorectal cancer (mCRC) [J] . J Souglakos, N Ziras, S Kakolyris, British Journal of Cancer . 2012,第3期

机译：CAPIRI（卡培他滨，伊立替康）加贝伐单抗与FOLFIRI（亚叶酸，5-氟尿嘧啶，伊立替康）加贝伐单抗的II期随机试验作为一线治疗不可切除的结肠癌（mCRC）患者
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
6. Randomised phase-II trial of CAPIRI (capecitabine irinotecan) plus bevacizumab vs FOLFIRI (folinic acid 5-fluorouracil irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) [O] . J Souglakos, N Ziras, S Kakolyris, 2012

机译：CAPIRI（卡培他滨伊立替康）加贝伐单抗与FOLFIRI（亚叶酸5-氟尿嘧啶伊立替康）加贝伐单抗的II期随机试验作为不可切除/转移性结直肠癌（mCRC）患者的一线治疗
7. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial [O] . Z Saridaki, N Androulakis, N Vardakis, 2012

机译：与Irinotecan（CPT-11），Oxaliplatin（LoHP），连续输注5-氟尿嘧啶和白草（Folfoxiri）加上西妥昔单抗作为克拉斯直肠直肠癌的一线治疗，转移结直肠癌：试验期II试验

CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress

著录项

相似文献

相关主题

期刊订阅